Objective: To assess how threshold oppositional defiant disorder (ODD), inattention, and hyperactivity-impulsivity affect the response to atomoxetine versus methylphenidate.
Method: Systematic review of randomized controlled trials (RCTs; ≥6 weeks follow-up). The primary measure was core symptom response-≥40% reduction in ADHD Rating Scale-IV-Parent Version: investigator administered and scored total or domain subscores, as appropriate.
Results: Data from 1,391 children and adolescents (823 atomoxetine, 568 methylphenidate; 7 RCTs) were meta-analyzed. The mean difference in response rates for patients with ODD was 0.6% (95% confidence interval [CI] = -11.9%-13.1%). The "without ODD" patient group showed significant between-trial heterogeneity (p < .001). Response rate differences for patients meeting the threshold for inattention or hyperactivity-impulsivity were -3.1% (95% CI = -11.5%-5.3%) and -4.9% (95% CI = -14.3%-4.4%), respectively.
Conclusions: Meeting the threshold criteria for oppositionality, inattention, or hyperactivity-impulsivity did not alter core ADHD symptom response to atomoxetine versus methylphenidate, which was equivalent.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1087054710389989 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common pediatric psychiatric disorders and is frequently diagnosed and treated by pediatricians. Stimulant medications are the first-line treatment for ADHD but may not be a good fit for many patients due to side effects, inadequate treatment response, or family preference. Non-stimulant ADHD medications provide a useful alternative for patients that cannot tolerate stimulants, have an incomplete treatment response to stimulants, are at risk for stimulant diversion, or whose family prefers to avoid stimulants.
View Article and Find Full Text PDFEffects of Age and Atomoxetine on Olfactory Perception and Learning and Underlying Plasticity Mechanisms in Rats.
Eur J Neurosci
January 2025
Biomedical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada.
The locus coeruleus (LC) plays a vital role in cognitive function through norepinephrine release. Impaired LC neuronal health and function is linked to cognitive decline during ageing and Alzheimer's disease. This study investigates age-related alterations in olfactory detection and discrimination learning, along with its reversal, in Long-Evans rats, and examines the effects of atomoxetine (ATM), a norepinephrine uptake inhibitor, on these processes.
View Article and Find Full Text PDFPrecision pharmacotherapy of atomoxetine in children with ADHD: how to ensure the right dose for the right person?
Front Pharmacol
October 2024
Pharmaceutical Sciences Research Center, Department of Pharmacy, Children's Hospital of Nanjing Medical University, Nanjing, China.
Non-stimulant atomoxetine is recognized in various current clinical guidelines as an important alternative to stimulants for the pharmacological treatment of attention deficit/hyperactivity disorder (ADHD) in children. While its efficacy and tolerability for core symptoms are established, there is considerable inter-individual variability in response and exposure, highlighting the need for personalized dosing. In this review, we evaluated existing studies and summarized comprehensive evidence supporting the clinical implementation of therapeutic drug monitoring (TDM) and personalized dosing of atomoxetine, organized around a series of logically structured questions.
View Article and Find Full Text PDFNoradrenergic modulation of saccades in Parkinson's disease.
Brain Commun
September 2024
Brain and Mind Centre and School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney 2050, Australia.
Noradrenaline is a powerful modulator of cognitive processes, including action decisions underlying saccadic control. Changes in saccadic eye movements are common across neurodegenerative diseases of ageing, including Parkinson's disease. With growing interest in noradrenergic treatment potential for non-motor symptoms in Parkinson's disease, the temporal precision of oculomotor function is advantageous to assess the effects of this modulation.
View Article and Find Full Text PDFFacile and Sustainable Electrostatic Integration of Eosin Y Dye for the Assay of the Atomoxetine Drug Through the Enhancement of the RRS Phenomenon.
J Fluoresc
October 2024
Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Assiut Branch, Al-Azhar University, Assiut, 71524, Egypt.
The suggested study follows specific protocols to guarantee that the atomoxetine drug analysis approach is environmentally friendly and sustainable. A number of recently created methods were used as prospective evidence for environmental sustainability and applicability, which is an essential point to emphasize. The current study introduces a new and very unique technology using ultrasensitive spectrofluorimetry to identify the atomoxetine (AXT) medication.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!